Bendamustine
- Generic Name
- Bendamustine
- Brand Names
- Belrapzo, Bendeka, Treanda, Vivimusta
- Drug Type
- Small Molecule
- Chemical Formula
- C16H21Cl2N3O2
- CAS Number
- 16506-27-7
- Unique Ingredient Identifier
- 9266D9P3PQ
- Background
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophili...
- Indication
Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma
- Associated Therapies
- -
Compassionate Use Re-Infusion of ATLCAR.CD30
- Conditions
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2021-12-03
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Registration Number
- NCT03914885
- Locations
- 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina, United States
Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-03-13
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Emory University
- Target Recruit Count
- 23
- Registration Number
- NCT03872180
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
🇺🇸Emory Johns Creek Hospital, Johns Creek, Georgia, United States
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2019-02-27
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT03856216
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age
- Conditions
- Interventions
- First Posted Date
- 2019-02-08
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 33
- Registration Number
- NCT03834688
- Locations
- 🇺🇸
Carle Cancer Center, Urbana, Illinois, United States
🇺🇸Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma
- First Posted Date
- 2019-01-28
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 114
- Registration Number
- NCT03817853
- Locations
- 🇳🇱
Albert Schweitzer Ziekenhuis - loc Dordrecht, Dordrecht, Netherlands
🇧🇷NOHC - Núcleo de Oncologia e Hematologia do Ceará, Fortaleza, CE, Brazil
🇺🇸San Juan Oncology Associates, Farmington, New Mexico, United States
Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL
- Conditions
- Interventions
- First Posted Date
- 2018-12-26
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 46
- Registration Number
- NCT03787264
- Locations
- 🇩🇪
Gemeinschaftspraxis Hämatologie Onkologie, Dresden, Germany
🇩🇪Universitatsklinik Carl Gustav Carus, Dresden, Germany
🇩🇪Praxis fuer Haematologie und Onkologie, Koblenz, Germany
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
- Conditions
- Interventions
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT03755804
- Locations
- 🇺🇸
Maine Children's Cancer Program, Scarborough, Maine, United States
🇺🇸St. Jude Affiliate Baton Rouge Clinic (Our Lady of the Lakes Regional Medical Center), Baton Rouge, Louisiana, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Emory University
- Target Recruit Count
- 54
- Registration Number
- NCT03739619
- Locations
- 🇺🇸
Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
🇺🇸Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
- First Posted Date
- 2018-10-05
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT03696784
- Locations
- 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients with R/r NHL and R/r B-cell ALL
- Conditions
- Interventions
- First Posted Date
- 2018-09-11
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Imugene Limited
- Target Recruit Count
- 129
- Registration Number
- NCT03666000
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸H. Lee Moffitt Cancer Center, Tampa, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.